Clinical studies on colds

COLDPREV study for ColdZyme® Mouth Spray
The study was conducted at the Ear, Nose and Throat Clinic at Skåne University Hospital in spring 2013 and shows that ColdZyme Mouth Spray reduces both the total viral load and the number of days with common cold symptoms in comparison to the placebo.  

The COLDPREV study was a randomized, double-blind placebo-controlled clinical study of ColdZyme Mouth Spray for colds. 46 subjects, both men and women (ages 20 to 46), were inoculated (infected) with the cold virus through the nose. The study was an initial pilot study aiming to serve as the foundation for larger studies and demonstrated a statistically significant difference between ColdZyme and the placebo in terms of the reduction of the total viral load in the throat (-99%) and the reduction of the number of days with common cold symptoms (-54%). 

The study was presented as an abstract and a poster at the XXXII Congress of the Nordic Association of Otolaryngology in Copenhagen on May 23, 2014. 

Link to the abstract.

A prospective study called COLDPREV II (link to ClinicalTrials.gov,  https://clinicaltrials.gov/ct2/show/NCT02479750) is being conducted in 2016 with the same design but on a larger scale in order to confirm the results of COLDPREV.

This content needs to be approved before viewing.
Yes, I accept
No, I decline